Stratos Wealth Partners’s InMed Pharmaceuticals INM Stock Holding History

Stratos Wealth Partners’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,076	Closed	-$16.7K	–	1760
2026 Q2	$16.7K	Buy	+1,076	New	+$11.9K	﹤0.01%	1686

Other funds holding INM

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Crestwood Advisors Group Boston, Massachusetts $6.76B AUM 24% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Stratos Wealth Partners's INM Position: Q3 2026 in Review

Stratos Wealth Partners sold out of InMed Pharmaceuticals (INM) in Q3 2026, closing a stake of 1,076 shares — an estimated $16.7K sold.

Stratos Wealth Partners first reported a position in INM in Q2 2026 and held it in 1 quarter. The position peaked at $16.7K in Q2 2026. 8 funds tracked by Wall St. Rank hold INM as of Q3 2026.

Stratos Wealth Partners reported no remaining InMed Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Stratos Wealth Partners sold 1,076 InMed Pharmaceuticals shares in Q3 2026, an estimated $16.7K.
Stratos Wealth Partners first reported a position in InMed Pharmaceuticals in Q2 2026 and held it in 1 quarter.
Stratos Wealth Partners's InMed Pharmaceuticals position peaked at $16.7K in Q2 2026.
8 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2026.

Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.